BioChem,
Journal Year:
2025,
Volume and Issue:
5(2), P. 9 - 9
Published: April 25, 2025
Oral
solid
drug
delivery
continues
to
be
the
gold
standard
in
pharmaceutical
formulations,
owing
its
cost-effectiveness,
ease
of
administration,
and
high
patient
compliance.
Tablets,
most
widely
used
dosage
form,
are
favored
for
their
precise
dosing,
simplicity,
economic
advantages.
Among
these,
controlled
release
(CR)
tablets
stand
out
ability
maintain
consistent
levels,
enhance
therapeutic
efficacy,
reduce
dosing
frequency,
thereby
improving
adherence
treatment
outcomes.
A
well-designed
CR
system
ensures
a
sustained
targeted
supply,
optimizing
performance
while
minimizing
side
effects.
This
review
delves
into
latest
advancements
with
particular
focus
on
hydrophilic
matrix
systems,
which
regulate
through
mechanisms
such
as
swelling,
diffusion,
erosion.
These
systems
rely
variety
polymers
drug-retarding
agents
achieve
tailored
profiles.
Recent
breakthroughs
crystal
engineering
polymer
science
have
further
enhanced
solubility
bioavailability,
addressing
critical
challenges
associated
poorly
soluble
drugs.
In
terms
manufacturing,
direct
compression
has
emerged
efficient
method
producing
tablets,
streamlining
production
ensuring
release.
The
integration
Quality
by
Design
framework
been
instrumental
product
systematically
linking
formulation
process
variables
patient-centric
quality
attributes.
advent
cutting-edge
technologies
artificial
intelligence
3D
printing
is
revolutionizing
field
formulations.
AI
enables
predictive
modeling
data-driven
optimization
profiles,
facilitates
development
personalized
medicines
highly
customizable
kinetics.
innovations
paving
way
more
patient-specific
therapies.
However,
regulatory
hurdles,
patent
constraints,
need
robust
vivo
validation
remain
significant
barriers
widespread
adoption
these
advanced
technologies.
succinct
underscores
synergistic
traditional
emerging
strategies
tablets.
It
highlights
potential
co-crystal
particularly
those
produced
via
compression,
improve
adherence,
deliver
superior
By
bridging
gap
between
established
practices
innovative
approaches,
this
poised
address
unmet
clinical
needs
advance
future
oral
delivery.
Pharmaceutics,
Journal Year:
2024,
Volume and Issue:
16(9), P. 1225 - 1225
Published: Sept. 19, 2024
:
Cellulose
derivatives
are
gaining
much
attention
in
medical
research
due
to
their
excellent
properties
such
as
biocompatibility,
hydrophilicity,
non-toxicity,
sustainability,
and
low
cost.
Unfortunately,
cellulose
does
not
exhibit
antimicrobial
activity.
However,
like
hydroxyethyl
represent
a
proper
matrix
incorporate
agents
with
beneficial
therapeutic
effects.
Traditional
thrombolytic
therapy
is
limited
by
low
specificity,
uncontrollable
bleeding
complications,
and
secondary
vascular
re-embolism.
To
address
this
issue,
we
developed
a
thrombin-responsive
sequential
targeted
nanoplatform
(MMSN-UK/TI@pep-Fuco)
for
efficient
thrombolysis
based
on
the
attack-defense-protection
integrated
strategy.
Herein,
multilevel
mesoporous
silica
nanoparticle
with
multiple
pore
sizes
was
synthesized
modified
fucoidan
(Fuco)
using
compound
peptide
(pep)
as
bridge
to
form
multifunctional
drug
carriers
MMSN@pep-Fuco.
Then,
urokinase
(UK)
tirofiban
(TI)
were
sequentially
loaded
into
MMSN@pep-Fuco
obtain
MMSN-UK/TI@pep-Fuco
nano
delivery
systems
(NDDS).
In
vitro
in
vivo
results
demonstrated
that
maintained
stability
blood
circulation
reduce
risk
(protection).
Once
arriving
at
thrombus
clots,
Fuco
facilitated
NDDS
identification
accumulation
via
P-selectin-mediated
active
targeting.
Thereafter,
coating
surface
of
shed
response
thrombin
then
allowed
quick
release
UK
from
larger
pores
achieve
rapid
(attack).
Next,
exposed
LS-MMSN/TI
core
NPs
can
continue
colonizing
sites,
TI
smaller
released
slowly
continuously
prevent
re-embolization
vessels
(defense).
Pharmacodynamic
showed
final
blockage
rate
treatment
group
only
4.87%
relatively
risk.
This
provided
new
strategy
arterial
thrombosis
related
diseases.